Aarti Pharmalabs Ltd Stock Price Today (NSE: AARTIPHARM)
Fundamental Score
Aarti Pharmalabs Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Aarti Pharmalabs Ltd share price today is ₹723.65, up +0.00% on NSE/BSE as of 17 February 2026. Aarti Pharmalabs Ltd (AARTIPHARM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.37K (Cr). The 52-week high for AARTIPHARM share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 26.57x, AARTIPHARM is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 14.54% and a debt-to-equity ratio of 0.32.
Aarti Pharmalabs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Aarti Pharmalabs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Aarti Pharmalabs Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while essential, presents unique risks for value investors. Regulatory hurdles and the constant need for innovation mean even established players can face significant headwinds. This analysis examines the "Aarti Pharmalabs share price" from the lens of a conservative value investor, prioritizing capital safety above all else. Currently trading around ₹776.80, with a PE ratio of 26.57, Aarti Pharmalabs Ltd warrants careful scrutiny.
Aarti Pharmalabs' Return on Capital Employed (ROCE) of 17.44% is a key metric for assessing its profitability and efficiency. While seemingly positive, its true impact on the company's "moat," or competitive advantage, requires deeper investigation. Does this ROCE translate into sustainable pricing power, or is it easily replicated by competitors? A consistently high ROCE, maintained over several years, would indicate a stronger moat than a single year's performance. Further examination is required to determine how effectively Aarti Pharmalabs' management allocates capital to generate these returns.
Compared to peers like
Mankind Pharma Ltd, evaluating management quality becomes crucial. Observing leadership's track record in navigating regulatory changes, managing debt, and allocating capital efficiently can significantly impact long-term shareholder value. Unlike Mankind Pharma Ltd, where high management credibility is already established, Aarti Pharmalabs needs to build that confidence through consistently conservative and value-oriented decisions. This includes maintaining a strong balance sheet and prioritizing organic growth over risky acquisitions.The observed PE ratio of 26.57 suggests a relatively high valuation compared to a classic deep value approach. A conservative investor would need to assess if future earnings growth can justify this premium. Further investigation into the company's debt levels, cash flow generation, and competitive landscape is necessary to determine the true margin of safety. This analysis is part of a more comprehensive 80-parameter fundamental audit verified by Sweta Mishra and is intended for informational purposes only.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarti Pharmalabs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AARTIPHARM across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Excellent ROCE Performance (17.44%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Interest Coverage (10.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Risk Factors
3 factors identified
Profit Decline Concern (-48.88%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-8.67%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-149.15 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Aarti Pharmalabs Ltd Financial Statements
Comprehensive financial data for Aarti Pharmalabs Ltd including income statement, balance sheet and cash flow
About AARTIPHARM (Aarti Pharmalabs Ltd)
Aarti Pharmalabs Ltd (AARTIPHARM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹6.37K (Cr). Aarti Pharmalabs Ltd has delivered a Return on Equity (ROE) of 14.54% and a ROCE of 17.44%. The debt-to-equity ratio stands at 0.32, reflecting the company's capital structure. Investors tracking AARTIPHARM share price can monitor key metrics including P/E ratio, promoter holding of 42.88%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
AARTIPHARM Share Price: Frequently Asked Questions
What is the current share price of Aarti Pharmalabs Ltd (AARTIPHARM)?
As of 17 Feb 2026, 10:07 am IST, Aarti Pharmalabs Ltd share price is ₹723.65. The AARTIPHARM stock has a market capitalisation of ₹6.37K (Cr) on NSE/BSE.
Is AARTIPHARM share price Overvalued or Undervalued?
AARTIPHARM share price is currently trading at a P/E ratio of 26.57x, compared to the industry average of 31.77x. Based on this relative valuation, the Aarti Pharmalabs Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of AARTIPHARM share price?
The 52-week high of AARTIPHARM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Aarti Pharmalabs Ltd share price?
Key factors influencing AARTIPHARM share price include quarterly earnings growth (Sales Growth: -8.67%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Aarti Pharmalabs Ltd a good stock for long-term investment?
Aarti Pharmalabs Ltd shows a 5-year Profit Growth of N/A% and an ROE of 14.54%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.32 before investing in AARTIPHARM shares.
How does Aarti Pharmalabs Ltd compare with its industry peers?
Aarti Pharmalabs Ltd competes with major peers in the Pharmaceuticals. Investors should compare AARTIPHARM share price P/E of 26.57x and ROE of 14.54% against the industry averages to determine competitive standing.
What is the P/E ratio of AARTIPHARM and what does it mean?
AARTIPHARM share price has a P/E ratio of 26.57x compared to the industry average of 31.77x. Investors pay ₹27 for every ₹1 of annual earnings.
How is AARTIPHARM performing according to Bull Run's analysis?
AARTIPHARM has a Bull Run fundamental score of 23.7/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AARTIPHARM belong to?
AARTIPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Aarti Pharmalabs Ltd share price.
What is Return on Equity (ROE) and why is it important for AARTIPHARM?
AARTIPHARM has an ROE of 14.54%, which shows decent profitability but room for improvement. ROE measures how efficiently Aarti Pharmalabs Ltd generates profits from shareholders capital.
How is AARTIPHARM debt-to-equity ratio and what does it indicate?
AARTIPHARM has a debt-to-equity ratio of 0.32, which indicates moderate leverage that should be monitored.
What is AARTIPHARM dividend yield and is it a good dividend stock?
AARTIPHARM offers a dividend yield of 0.71%, meaning you receive ₹0.71 annual dividend for every ₹100 invested in Aarti Pharmalabs Ltd shares.
How has AARTIPHARM share price grown over the past 5 years?
AARTIPHARM has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in AARTIPHARM and why does it matter?
Promoters hold 42.88% of AARTIPHARM shares, with 0.01% pledged. High promoter holding often indicates strong management confidence in Aarti Pharmalabs Ltd.
What is AARTIPHARM market capitalisation category?
AARTIPHARM has a market capitalisation of ₹6371 crores, placing it in the Mid-cap category.
How volatile is AARTIPHARM stock?
AARTIPHARM has a beta of N/A. A beta > 1 suggests the Aarti Pharmalabs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AARTIPHARM operating profit margin trend?
AARTIPHARM has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is AARTIPHARM quarterly performance?
Recent quarterly performance shows Aarti Pharmalabs Ltd YoY Sales Growth of -8.67% and YoY Profit Growth of -48.88%.
What is the institutional holding pattern in AARTIPHARM?
AARTIPHARM has FII holding of 8.02% and DII holding of 6.95%. Significant institutional holding often suggests professional confidence in the Aarti Pharmalabs Ltd stock.